Findings support lower doses of atropine in pediatric myopia Rx

Findings support lower doses of atropine in pediatric myopia rx

(HealthDay)—Adverse effects are less frequent at lower doses of atropine, and higher doses are not more effective in reducing progression of myopia in children, according to a meta-analysis published online May 11 in JAMA Ophthalmology.

Qianwen Gong, M.D., from Sichuan University in Chengdu, China, and colleagues examined the efficacy versus the of in treatment of myopia in children in and cohort studies. Data were included for 19 unique studies with 3,137 unique children, aged younger than 18 years.

The researchers found that the weighted mean differences between the atropine and control groups in myopia progression were 0.50, 0.57, and 0.62 diopters per year for low-, moderate-, and high-dose atropine, respectively (P < 0.001), which translated to a high effect size (Cohen d of 0.97, 1.76, and 1.94, respectively). With respect to progression, all doses of atropine were equally beneficial (P = 0.15). There were more adverse effects with high-dose atropine (incidence of photophobia, 43.1, 17.8, and 6.3 percent, respectively, for high-, moderate-, and low-dose atropine; P = 0.03). There were no differences in the incidence of adverse effects between Asian and white patients (P = 0.37 for photophobia).

"This meta-analysis suggests that the efficacy of atropine is dose independent within this range, whereas the adverse effects are dose dependent," the authors write.

Explore further

Nearsightedness progression in children slowed down by medicated eye drops

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: JAMA Ophthalmology

Copyright © 2017 HealthDay. All rights reserved.

Citation: Findings support lower doses of atropine in pediatric myopia Rx (2017, May 18) retrieved 12 April 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments